Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT. Wiczer TE, et al. Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12. Blood Adv. 2017. PMID: 29296820 Free PMC article.
A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK, Wiczer TE, Erdeljac HP, Van Deusen KR, Porter K, Philips G, Wang TF. Phelps MK, et al. Among authors: wiczer te. J Oncol Pharm Pract. 2019 Jun;25(4):793-800. doi: 10.1177/1078155218757856. Epub 2018 Feb 20. J Oncol Pharm Pract. 2019. PMID: 29460705
Hypertension and incident cardiovascular events following ibrutinib initiation.
Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhat S, Byrd JC, Woyach JA, Awan F, Addison D. Dickerson T, et al. Among authors: wiczer t. Blood. 2019 Nov 28;134(22):1919-1928. doi: 10.1182/blood.2019000840. Blood. 2019. PMID: 31582362 Free PMC article. Clinical Trial.
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.
Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, Guerrero T, Levine LB, Lucas F, Shindiapina P, Sigmund AM, Sullivan M, Wiczer TE, Woyach JA, Awan FT. Rogers KA, et al. Among authors: wiczer te. Leukemia. 2019 Oct;33(10):2527-2530. doi: 10.1038/s41375-019-0481-1. Epub 2019 May 13. Leukemia. 2019. PMID: 31086260 Free PMC article. No abstract available.
13 results